In a prospective comparative study evaluating rapid diagnostic approaches for severe bloodstream infections, automated phenotypic testing platforms and laboratory automation significantly reduced inconclusive results compared with conventional agar disk diffusion while presenting assay-specific diagnostic error profiles. Investigating positive blood cultures containing Gram-negative bacteria, researchers evaluated five different rapid antimicrobial susceptibility testing assays directly against standard reference methods. The study established that fully automated systems measuring minimum inhibitory concentrations delivered a substantially higher proportion of actionable readings than manual agar plates, yet each platform demonstrated distinct diagnostic vulnerabilities that require targeted laboratory oversight.
Bacterial bloodstream infection and its escalation into sepsis remain life-threatening clinical emergencies characterized by substantial mortality rates. The therapeutic management of these conditions has grown increasingly difficult due to the global dissemination of antimicrobial resistance among Gram-negative pathogens, where the production of extended-spectrum beta-lactamases or carbapenemases can render standard first-line therapies ineffective. Because prompt initiation of targeted antibiotic therapy directly influences patient outcomes, the European Committee on Antimicrobial Susceptibility Testing established a standardized rapid antimicrobial susceptibility testing protocol. This protocol permits testing directly from positive blood culture bottles without requiring intermediate sub-culturing steps, allowing certain bacterial isolates to be evaluated after as few as four hours of incubation.
Despite its clinical promise, the conventional agar-based disk diffusion method faces operational challenges that conflict with modern laboratory automation goals. Manual disk diffusion requires labor-intensive setup, manual extraction of plates from incubators for measurement, and subjective manual caliper or rule readings of faint inhibition zone edges after short incubation periods. Furthermore, standard disk diffusion lacks minimum inhibitory concentration values needed to guide precise dosage titration, and official clinical breakpoints remain established for only nine Gram-negative species. To assess whether modern technology overcomes these limitations, investigators conducted an eight-month prospective evaluation across three microbiological laboratories in Graz, Austria, analyzing positive blood culture bottles processed directly at the Diagnostic and Research Institute of Hygiene, Microbiology, and Environmental Medicine at the Medical University of Graz under an approved ethical protocol.
The evaluation encompassed ninety-seven confirmed Gram-negative blood culture samples after excluding thirteen specimens that failed pre-established inclusion criteria. The scientific team evaluated five distinct rapid testing platforms: conventional manual disk diffusion performed in strict accordance with the European Committee on Antimicrobial Susceptibility Testing protocol with visual readings taken at four, six, and eight hours; automated incubation and on-screen digital zone measurement utilizing the BD Kiestra Total Lab Automation system at identical time intervals; two fully automated minimum inhibitory concentration systems, namely VITEK Reveal and dRAST; and the Biofire FilmArray BCID2 multiplex polymerase chain reaction panel designed to detect species identities and forty-three diagnostic targets, including key resistance genes.
Reference identifications were confirmed using matrix-assisted laser desorption ionization–time of flight mass spectrometry, while reference susceptibility profiles were derived using the VITEK 2 instrument, gradient diffusion strips, or broth microdilution evaluated under the 2024 European guidelines. Across the cohort, background resistance remained moderate: none of the ninety-seven blood culture samples harbored colistin- or carbapenem-resistant pathogens, and extended-spectrum beta-lactamase production was confirmed in seven isolates. The Biofire BCID2 molecular assay demonstrated complete concordance with reference standards, achieving one hundred percent sensitivity and specificity by correctly identifying all ninety-six tested blood culture isolates and detecting all seven extended-spectrum beta-lactamase producers without generating false-positive resistance calls, though nine isolates could only be resolved to genus or order level due to panel design constraints.
A critical divergence observed among the phenotypic platforms involved species eligibility and the proportion of tests falling within the area of technical uncertainty. For agar-based disk diffusion, clinical zone diameter breakpoints were available for only seventy-two percent of isolates at the four-hour mark and eighty-one percent after six to eight hours. Conversely, panel coverage of the clinical samples reached ninety-four percent for VITEK Reveal, ninety-nine percent for Biofire, and one hundred percent for dRAST. Consequently, VITEK Reveal and dRAST generated interpretable results for 93.1 percent and 96.8 percent of tests, respectively, whereas manual disk diffusion and the BD Kiestra system produced interpretable findings in only 63.6 to 75.6 percent of evaluations. The manual and automated agar assays assigned between 7.5 and 14.9 percent of all measurements to the area of technical uncertainty, compared with just 0.6 percent for VITEK Reveal and 1.1 percent for dRAST.
Across 6,036 analyzed phenotypic susceptibility tests, overall categorical agreement with reference standards varied significantly from 82.2 percent for four-hour manual disk diffusion to 95.4 percent for VITEK Reveal. Prolonged incubation significantly enhanced categorical agreement for both agar-based techniques, with eight-hour incubation demonstrating statistically superior agreement over four-hour reads for conventional disk diffusion and the BD Kiestra platform. The BD Kiestra automated system outperformed manual disk diffusion during early four-hour evaluations by generating higher categorical agreement and fewer uninterpretable reads. When results located in the area of technical uncertainty were excluded from analysis, agar-based methods demonstrated overall error rates between 0.8 and 2.9 percent, indicating that technical uncertainty rather than explicit misclassification drove the lower initial agreement of agar plates.
Detailed examination of categorical errors exposed notable system-specific liabilities between the automated platforms. VITEK Reveal recorded an overall error rate of 4.1 percent driven by a very major error rate of 2.4 percent, representing false-susceptible classifications that could misdirect clinical antimicrobial selection. These false-susceptible determinations clustered predominantly within beta-lactam antibiotics, which accounted for twenty-one of the twenty-two very major errors observed with the instrument. In amoxicillin-clavulanic acid testing, VITEK Reveal classified fifteen isolates as ampicillin-resistant but amoxicillin-clavulanic acid-susceptible; thirteen of those thirteen evaluations represented false-susceptible calls, yielding a positive predictive value of only thirteen percent for detecting amoxicillin-clavulanic acid susceptibility in ampicillin-resistant strains.
In contrast, the dRAST system exhibited an overall error rate of 6.2 percent characterized by an exceptionally low very major error rate of 0.4 percent but an elevated major error rate of 3.4 percent, denoting false-resistant determinations. This tendency toward false resistance was especially pronounced in motile bacteria: sixteen of thirty-two false-resistant dRAST findings occurred in Proteus mirabilis isolates, which constituted only six percent of the cohort. Microscopic review confirmed motility in saline suspensions for the remaining isolates generating major errors. The authors noted that dRAST tracks single-cell duplication in semi-solid media using microscopic imaging, suggesting that active cellular motility may generate optical artifacts that mislead the image-analysis algorithm into counting single moving bacteria as dividing doublets.
Drug-specific analyses further illustrated these performance characteristics across primary therapeutic categories. For piperacillin-tazobactam, agar methods produced discrepant area of technical uncertainty readings in up to 53.7 percent of tests, while VITEK Reveal yielded a 4.6 percent very major error rate and dRAST produced a 6.7 percent major error rate. In cephalosporin evaluations, dRAST produced a major error rate of 6.0 percent, whereas VITEK Reveal produced false-susceptible results across cefotaxime, ceftazidime, and cefepime for a single Klebsiella pneumoniae isolate. Testing for carbapenem susceptibility showed elevated area of technical uncertainty rates for manual disk diffusion at four hours, whereas dRAST yielded eleven false-intermediate or false-resistant determinations, eight of which occurred in Proteus mirabilis. Susceptibility agreement across all platforms remained consistently high for gentamicin and trimethoprim-sulfamethoxazole, with no very major errors observed during ciprofloxacin testing.
The study authors concluded that while automated rapid susceptibility systems provide substantial operational advantages by expanding species coverage and eliminating the high rates of technical uncertainty seen on agar plates, their diagnostic quirks demand concrete laboratory mitigation strategies. Facilities implementing VITEK Reveal should consider confirming susceptible amoxicillin-clavulanic acid findings in ampicillin-resistant isolates prior to reporting, while laboratories utilizing dRAST should establish validation rules accounting for motile organisms like Proteus mirabilis. Although the low prevalence of multidrug-resistant and carbapenemase-producing pathogens represents an acknowledged limitation requiring broader follow-up trials, this prospective head-to-head comparison delineates the specific technical trade-offs laboratories encounter when transitioning from manual agar protocols to automated rapid bacteremia diagnostics.
Subject of Research: Prospective comparative evaluation of automated and manual rapid antimicrobial susceptibility testing assays in Gram-negative bacteremia
Article Title: Comparison of Five Assays for Rapid Antimicrobial Susceptibility Testing (RAST), Including Disk Diffusion, MIC-Based Systems, and Genotypic Methods: A Prospective Evaluation
Article References: Uitz, C., Siebenhofer, D., Aurenhammer, K., Krause, R., Kroißenbrunner, M., Kuenzer, T., Steinmetz, I., & Dichtl, K. (2026). Comparison of Five Assays for Rapid Antimicrobial Susceptibility Testing (RAST), Including Disk Diffusion, MIC-Based Systems, and Genotypic Methods: A Prospective Evaluation. Infectious Diseases and Therapy, 15(12), 3357-3375. https://doi.org/10.1007/s40121-026-01451-z
Image Credits: AI Generated
DOI: 10.1007/s40121-026-01451-z
Keywords: rapid antimicrobial susceptibility testing, RAST, bloodstream infections, bacteremia, Gram-negative bacteria, disk diffusion, BD Kiestra, VITEK Reveal, dRAST, Biofire BCID2, EUCAST, minimum inhibitory concentration, extended-spectrum beta-lactamase, Proteus mirabilis, antimicrobial resistance, clinical microbiology
News Source: Ophelia Keating. (November 20, 2026). Automated Bloodstream Infection Assays Outperform Manual Disk Diffusion Despite Specific Diagnostic Errors. Scienmag.



